CILOSTAZOL FOR STROKE IN SMALL VESSEL DISEASE: SYSTEMATIC REVIEW OF CURRENT LITERATURE

Rizaldy Taslim Pinzon

Abstract


Introduction: Cerebral small vessel disease (SVD) is accounted for 25% of ischemic stroke pathology. Cilostazol is a therapeutic option for secondary ischemic stroke prevention, especially in subgroups with high risks for hemorrhagic events. The available evidences are limited for optimal management of stroke in cerebral SVD.

Objective: This systematic review aimed to identify the effectiveness of cilostazole for stroke in SVD

Method: This systematic research was done by two authors using mainly PubMed and Cochrane as a database. The terms used to search the literatures were “Cilostazol”, “Small Vessel Infarction”, “Lacunar Infarction”, “Ischemic Stroke”, and “Clinical Trial”. We measure the quality of the clinical trials using Jadad Score. If the trial manage to meet the 3 important features then the jadad score of the trial will be 3.

Results: The journal form PubMed and Cohrane was up to 3848 journals that were screened. The reviewers then begins to screening on the journals, exclude all of the irrelevant, and duplication study and make sure the inclusion and exclusion criteria were fulfilled. The result was 3 RCT studies. All studies has a good Jadad score. All of the comparison used in the studies is aspirin except for the study of Han, et al. (2014), that compare cilostazol with placebo. All of the subject that were used is above the age of 30 y.o. and the length of treatment is above 3 months. Each of the outcome in all of the RCT studies is different, but their aims is to measure the effectiveness or the efficacy of cilostazol. Huang, et al (2008) have the most subject (720 subjects) and Lee, et al (2017), have the least subject (80 subjects).

Conclusion:

Key words: cilostazol, stroke, small vessel disease


Full Text:

PDF

References


Mathew E, Chandrika C, Preethy MK. A prospetive observational study on prescribing trends and adverse drug reactions in stroke patients. IJPPS 2017;9(7):25-30.

Spurthi I, Gowthami B, Khyathi D, Vinod G. Risk element and drug utilization in stroke patients. IJPPS 2016;8(10):290-292.

Dabertrand F, Kroigaard C, Bonev AD, Cognat E, Dalsgaard T, Domenga-Denier V, Hill-Eubanks D, Brayden JE, Joutel A, Nelson MT. Potassium channelopathy-like defect underlies early-stage cerebrovascular dysfunction in a genetic model of small vessel disease. PNAS 2015;doi:0.1073/pnas.1420765112.

Joutel A, Faraci FM. Cerebral small vessel disease (SVD): Insights and opportunities from mouse models of collagen IV-related SVD and CADASIL. Stroke 2014;45(4):1215–1221.

Pantoni L. Cerebral SVD: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol 2010;9(7):689-701.

Rincon F, Wright C. Current pathophysiological concepts in cerebral small vessel disease. Frontiers in Aging Neuroscience 2014;6(24):1-8.

Ostergaard L, Engedal TS, Moreton F, Hansen MB, Wardlaw JM, Dalkara T, Markus HS, Muir KW. Cerebral SVD: Capillary pathways to stroke and cognitive decline. Journal of Cerebral Blood Flow & Metabolism 2016;6(2):302–325.

Shi Y, Wardlaw JM. Update on cerebral SVD: a dynamic whole-brain disease. Stroke and Vascular Neurology 2016;1:e000035;doi:10.1136/svn-2016000035.

Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, Lindley RI, O'Brien JT, Barkhof F, Benavente OR, Black SE, Brayne C, Breteler M, Chabriat H, Decarli C, de Leeuw FE, Doubal F, Duering M, Fox NC, Greenberg S, Hachinski V, Kilimann I, Mok V, Oostenbrugge R, Pantoni L, Speck O, Stephan BC, Teipel S, Viswanathan A, Werring D, Chen C, Smith C, van Buchem M, Norrving B, Gorelick PB, Dichgans M & nEuroimaging, S. T. f. R. V. c. o. 2013. Neuroimaging standards for research into SVD and its contribution to ageing and neurodegeneration. Lancet Neurol 2013; 12:822-38.

Charidimou A, Pantoni L, Love S. The concept of sporadic cerebral SVD: A road map on key definitions and current concepts. International Journal of Stroke 2016;11(1):6–18.

Wardlaw JM, Smith C, Dichgans M. Mechanisms underlying sporadic cerebral SVD: insights from neuroimaging. Lancet Neurol. 2013;12(5):1-27.

Choi JC. Genetics of Cerebral Small Vessel Diseas. Journal of Stroke 2015; 17(1):7-16.

Kim BJ, Lee SH. Prognostic impact of cerebral SVD on stroke outcome. Journal of Stroke 2015;17(2):101-110.

Behrouz R, Malek AR, Torbey MT. Small vessel cerebrovascular disease: the past, present, and future. Stroke Research and Treatment 2012;doi:10.1155/2012/839151.

Bath PM, Wardlaw JM. Pharmacological treatment and prevention of cerebral small vessel disease: a review of potential interventions. International Journal of Stroke 2015; 10:469-478.

Lee SJ, Lee JS, Choi MH, Lee SE, Shin DH, Hong JM. Cilostazol improves endothelial function in acute cerebral ischemia patients: a doubleblind placebo controlled trial with flow mediated dilation technique. Neurology 2017;17:169.

Mok V, Kim JS. Prevention and management of cerebral small vessel disease. Journal of Stroke 2015;17(2):111-122.

Son JD, Cho SM, Choi YW, Kim SH, Kwon IS, Jin EH, Kim JW, Hong JH. Pharmacokinetic characteristics of cilostazol 200 mg controlled-release tablet compared with two cilostazol 100 mg immediate-release tablets (Pletal) after single oral dose in healthy Korean male volunteers. Transl Clin Pharmacol 2016; 24(4):183-188.

Park JS, Kim YJ. The clinical effects of cilostazol on atherosclerotic vascular disease. Korean Circ J 2008; 38:441-445.

Hiatt WR, Money SR, Brass EP. Long-term safety of cilostazol in patients with peripheral artery disease: The CASTLE study (Cilostazol: A Study in Long-term Effects). J Vasc Surg 2008;47:330-6.

Han SW, Lee SS, Kim SH et al. Effect of cilostazol in acute lacunar infarction based on pulsatility index of transcranial Doppler (ECLIPse): a multicenter, randomized, double-blind, placebo-controlled trial. Eur Neurol 2013;69:33–40.

Uchiyama S, Shinohara Y, Katayama Y, Yamaguchi T, Handa S, Matsuoka K, Ohashi Y, Tanahashi N, Yamamoto H, Genka C, Kitagawa Y, Kusuoka H, Nishimaru K, Tsushima M, Koretsune Y, Sawada T, Hamada C. Benefit of Cilostazol in Patients with High Risk of Bleeding: Subanalysis of Cilostazol Stroke Prevention Study 2. Cerebrovasc Dis 2014;37:296–303.

Angiolillo D, Capranzano P, Goto S, Aslam M, Desai B, Charlton RK, Suzuki Y, Box LC, Shoemaker SB, Zenni MM, Guzman LA, Bass TA. A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. European Heart Journal 2008; 29:2202–2211.

Toyoda K, Uchiyama S, Hoshino H, Kimura K, Origasa H, Naritomi H, Minematsu K, Yamaguchi T, CSPS.com Study Investigators. Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial. International Journal of Stroke 2015; 10:253-258.

Berger VW, Alperson SY. 2009. A General framework for the evaluation of clinical trial quality. Rev Recent Clinical Trials; 4(2):79–88.

Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JPA, Clarke M, Devereaux PJ, Kleijnen J, Moher D. 2009. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ; 339:b2700.

Huang Y, Cheng Y, Wu J, Li Y, Xu E, Hong Z, Li Z, Zhang W, Ding M, Gao X, Fan D, Zeng J, Wong K, Lu C, Xiao J, Yao C. Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study. Lancet Neurol. 2008 Jun; 7(6):494-499.

Ueno H, Koyama H, Mima Y, Fukumoto S, Tanaka S, Shoji T, Emoto M, Shoji T, Nishizawa Y, Inaba M. Endothelial progenitor cells and small-dense LDl cholesterol in diabetic patients with cerebral ischemia: a randomized controlled pilot trial. Journal of Atherosclerosis and Thrombosis 2011;18(10):883-890.

Han SW, Song TJ, Bushnell CD, Less SS, Kim SH, Lee JH, Kim GS, Kim OJ, Koh IS, Lee JY, Suk SH, Lee SI, Nam HS, Kim WJ, Lee KY, Park JH, Kim JY, Park JH. Cilostazol Decreases Cerebral Arterial Pulsatility in Patients with Mild White Matter Hyperintensities: Subgroup Analysis from the Effect of Cilostazol in Acute Lacunar Infarction Based on Pulsatility Index of Transcranial Doppler (ECLIPse) Study. Cerebrovasc Dis 2014; 38:197-203.

Haungsaithong R, Udommongkol C, Nidhinandana S, Chairungsaris P, Chinvarun Y, Suwantamee J, Sithinamsuwan P. The changes in mean platelet volume after using of antiplatelet drugs in acute ischemic stroke: a randomized controlled trial. J Med Assoc Thai 2015; 98 (9): 852-7.

Fujimoto S, Osaki M, Kanazawa M, Tagawa N, Kumamoto M, Ohya Y, Kitazono T. Effect of oral cilostazol on acute neurological deterioration and outcome of noncardioembolic minor stroke. Journal of Clinical Gerontology & Geriatrics 2016; 7:21-26.


Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.